Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters.com
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotechnology
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Profit Outlook
Why Puma Biotechnology's Shares Jumped 20% on Monday | The Motley Fool
Puma Biotechnology
Puma Biotechnology (PBYI) Stock Climbs On Orphan Drug Designation | Alpha Stock News
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
PharmaShots - Incisive news in 3 shots on Twitter: "Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer https://t.co/KKTvnp68jJ https://t.co/LR02TGd4oT" / Twitter
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Puma Wins 5-Year Extension of Patent on Main Breast Cancer Treatment Drug Nerlynx - Los Angeles Business Journal
Articles with Puma Biotechnology
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Puma Biotechnology | Evaluate
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer | Business Wire
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Exhibitor Puma Biotechnology 02-20 - Scripps CME Connection
